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Background: Overexpression of microRNA-182 (miR-182) is found in various human cancers, including non-small
cell lung cancer (NSCLC). Our aim is to investigate the association of miR-182 expression with the sensitivity of
NSCLC to cisplatin.
Methods: TaqMan RT-PCR or Western blot assay was performed to detect the expression of mature miR-182 and
programmed cell death 4 (PDCD4) protein. miR-182 and (or) PDCD4 depleted cell lines were generated using
miR-182 inhibitor and (or) siRNA. The viabilities of treated cells were analyzed using MTT assay.
Results: The expression level of miR-182 in A549 cell line was significantly higher than that in NHBE cell line
(p < 0.01). Transfection of miR-182 inhibitor induced sensitivity of A549 cells to cisplatin. A549 cells transfected with
PDCD4 siRNA became more resistant to cisplatin therapy. We found an increase PDCD4 protein level following the
transfection of miR-182 inhibitor using Western blot analysis. In addition, the enhanced growth-inhibitory effect by
miR-182 inhibitor was weakened after the addition of PDCD4 siRNA.
Conclusions: The results of the present study demonstrated that overexpression of miR-182 may involve in
chemoresistance of NSCLC cells to cisplatin by down-regulating PDCD4.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1793467320130186
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Lung cancer is the most common cancer in the world,
with a survival rate of 15% [1]. Approximately 1.6 mil-
lion cases of lung cancer have occurred in 2008, of
which 80% were non-small cell lung cancer (NSCLC).
Surgical resection is known as the most effective treat-
ment for NSCLC, however, due to the fact that most
diagnoses were confirmed in an advanced stage, only a
few patients can be cured by surgical treatment. Patients
with NSCLC are mostly treated with platinum-based
chemotherapy. However, the development of chemore-
sistance is a major obstacle limiting successful treatment
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unless otherwise stated.chemoresistance are accordingly of great interest in lung
cancer chemotherapy [3,4].
MicroRNAs (miRNAs) are small non-coding RNAs of
20 ~ 22 nucleotides. It represses gene expression through
interaction with 3′untranslated regions (UTRs) of mRNAs.
miRNAs are predicted to target over 50% of all human
protein-coding genes, enabling them to have numerous
regulatory roles in many physiological and developmental
processes, including development, differentiation, apop-
tosis and proliferation, through imperfect pairing with
target mRNAs of protein-coding genes and the tran-
scriptional or post-transcriptional regulation of their ex-
pression [5,6]. miR-182 is one of the miRNAs often seen
upregulated in cancers. Several studies have reported
miR-182 to be upregulated in NSCLC [7]. Furthermore,
miR-182 functions as an oncomiR to enhance cancer
cell proliferation [8,9]. Recent studies indicated thatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Husted et al. found that miR-182 was consistently up-
regulated in the multidrug resistant Ehrlich ascites
tumor cells [10]. Therefore, we hypothesized that the
up-regulation of miR-182 may be related to chemother-
apy resistance in NSCLC, but the molecular mechanism
remains unclear.
As an important tumor suppressor, programmed cell
death 4 (PDCD4) influences transcription and transla-
tion of multiple genes, and modulates different signal
transduction pathways. However, the upstream regula-
tion of this gene is largely unknown. Until now, the
mainly identified miRNA that directly targets PDCD4 is
microRNA-21 (miR-21). MiR-21 has been found to
negatively regulate PDCD4 expression in breast cancer,
colorectal cancer, and ovarian cancer [11-13]. However,
other potential PDCD4-targeting miRNAs remains to be
defined. We speculate that miR-182 may play an import-
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Medical College Affiliated Hospital approved this study.
The human lung adenocarcinoma cell line A549 was
purchased from the Cell Bank of Chinese Academy of
Sciences (Shanghai, China). A549 cell line was cultured
in DMEM containing 10% fetal bovine serum (Gibco®,
Invitrogen, Carlsbad, CA, USA), 100 units/ml penicillin,
and 100 μg/ml streptomycin at 37°C in a 5% CO2 humidi-
fied incubator to the log phase of proliferation before
harvesting the cells. Normal human bronchial epithelial
cells (NHBE) (Clonetics™) were maintained in a culture
medium according to the protocol provided by Clonetics™.
Drugs and reagents
Cisplatin was purchased from QiLu Pharmaceutical
(Jinan, China). MiR-182 inhibitor, PDCD4 siRNA, and
their negative control oligonucleotides were obtained
from Shanghai GeneChem Co., Ltd (Shanghai, China).
These were used to transfect A549 cells using Lipofecta-
mine™ 2000 (Invitrogen, Carlsbad, CA, USA) according
to the instructions provided by the manufacturer. Mono-
clonal rabbit anti-human PDCD4 antibody (Cell Signal-
ing Technology, Inc., Beverly, MA, USA) was used for
Western blot analysis.
MTT assay
Cells transfected with miR-182 inhibitor or siRNA-PDCD4
were seeded into 96-well plates at 6*103 cells/well and
allowed to grow overnight, and then were treated with dif-
ferent concentrations of cisplatin. After 24 h of treatment,
20ul of 5 mg/ml MTT reagent (Sigma-Aldrich, St. Louis,MO, USA) was added and incubated in the dark for 4 h.
The absorbance of the plate was measured in a microplate
reader at a wavelength of a 570-nm reference (BMG Lab
Technologies, Germany), and the results were expressed as
the percentage of absorbance relative to untreated controls.
Each treatment was carried out in triplicate.
Real-time quantitative reverse transcription-PCR for
miRNA expression and mRNA expression
For miRNA expression detection, reverse transcription
(RT) reaction was performed with PrimeScript® RT re-
agent Kit (TAKARA BiotechnologyCO., LTD., Dalin,
China) and realtime quantitative RT-PCR (qRT-PCR) was
performed using SYBR® Premix Ex Taq™ II (TAKARA Bio-
technology CO., LTD., Dalin, China) on the basis of the
protocol provided by the manufacturer. For mRNA ex-
pression detection, reverse transcription reaction was
performed with PrimeScript® RT reagent Kit (TAKARA
Biotechnology CO., LTD., Dalin, China) and RT-PCR
(qRT-PCR) was performed using SYBR® Premix Ex Taq™
II (TAKARA Biotechnology CO., LTD., Dalin, China).
The designed PCR primers were as follows: PDCD4
forward primer, 5’-GGCCTCCAAGGAGTAAGACC-3’;
PDCD4 reverse primer, 5’-AGGGGTCTACATGGCAA
CTG-3’; GAPDH forward primer, 5’-AAGGGAAGGTT
GCTGGATAGG-3’; GAPDH reverse primer, 5’-CACA
TCCACCTCCTCCACATC-3’. The expression of the
target miRNA was normalized relative to that of the in-
ternal control, U6 and the expression of the target gene was
normalized relative to the expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), which was used as an
internal control. Data were analyzed according to the com-
parative Ct method also referred to as the 2−ΔΔCT method.
Western blot assay
The proteins were resolved on an SDS denaturing poly-
acrylamide gel and then transferred onto a nitrocellulose
membrane. Antibody to PDCD4 or GAPDH was incu-
bated with the membranes overnight at 4°C. The mem-
branes were washed and incubated with horseradish
peroxidase (HRP)-conjugated secondary antibodies. Pro-
tein expression was assessed by enhanced chemilumines-
cence and exposure to chemiluminescent film. LabWorks™
Image Acquisition and Analysis Software (UVP, Upland,
CA) were used to quantify the band intensities. All the
antibodies were purchased from Abcam (Cambridge, MA).
Statistical analysis
All the experiments were carried out in triplicate. The
quantitative values were expressed as mean ± standard
deviation (SD), and the hypothesis test for significance
between two groups utilized the Student’s t test. Statis-
tical significance was set as p <0.05.
Figure 2 Transfection of miR-182 inhibitor and its negative
control oligonucleotides (NC) into A549 cells. qRT-PCR showed
significant under-expression of miR-182 in the transfected cells
compared with control cells.
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MiR-182 was upregulated in human lung adenocarcinoma
cell line A549
To define the role of miR-182 in human lung cancer
tumorigenesis, we compared the expression levels of
miR-182 in human lung cancer cell line A549 and NHBE
cell line (normal human bronchial epithelial cells) by
qRT-PCR. The expression level of miR-182 in A549 was
significantly higher than that in NHBE cell line (p < 0.01,
Figure 1).
Transfection of miR-182 inhibitor induced sensitivity of
A549 cells to cisplatin
To further assess the effect of miR-182, we transfected
miR-182 inhibitor and its negative control oligonucleo-
tides into A549 cells. Transfection of cells with miR-182
inhibitor suppressed miR-182 level compared with the
control cells (shown in Figure 2). The MTT assay showed
that the miR-182-suppressed cells were significantly more
sensitive to the therapy of cisplatin than control cells
(shown in Figure 3).
PDCD4 was a target of miR-182 and responsible for the
miR-182-induced resistance in A549 cells
We transfected A549 cells with miR-182 inhibitor or a
scrambled miR-182 inhibitor control. The PDCD4 mRNA
level was overexpression in miR-182-suppressed cells
compared with controls (shown in Figure 4a). We exam-
ined the protein levels of PDCD4 following the transfec-
tion of miR-182 inhibitor in A549 cells by Western blot
analysis and found that cells transfected with miR-182 in-
hibitor showed an increase PDCD4 protein expression
(shown in Figure 4b). Down regulation of PDCD4 expres-
sion by siRNAs, A549 cells became more resistant to
the therapy of cisplatin (shown in Figure 5). In addition,
the enhanced growth-inhibitory effect by the miR-182Figure 1 MiR-182 was up-regulated in A549 cell line compared
to that in NHBE cell line (p < 0.01).inhibitor transfection was weakened after the addition
of PDCD4 siRNA (shown in Figure 5).Discussion
Although chemotherapeutic agents are widely used in
the treatment of lung cancer, their efficacy is often lim-
ited by the existence or development of chemoresis-
tance. As one of the first-line chemotherapeutic agents
for the treatment of NSCLC, cisplatin is a platinum-
based compound that forms intra- and inter-strand
adducts with DNA [14,15]. Despite tremendous efforts,
cisplatin treatment often results in the development of
drug resistance, leading to therapeutic failure, and the
molecular mechanisms leading to cisplatin chemoresis-
tance are poorly understood. Factors that enhance theFigure 3 MTT assay revealed that the anti-tumour effects
cisplatin in the miR-182 downregulated cells were significantly
profound than in control cells (*P <0.05). Data are mean ± SD of
three experiments.
Figure 4 Evaluation of PDCD4 in A549cells transfected with
miR-182 inhibitor and its negative control oligonucleotides
(NC). A. qRT-PCR showed significant upregulation of PDCD4 mRNAs
in the transfected cells. B. Western blot analysis demonstrated
significant overexpression of PDCD4 proteins in the transfected
cells (*P < 0.05). Data are mean ± SD of three experiments.
Figure 5 Changes in anti-tumour effects of the cisplatin after
transfection of anti-miR-182 and/or siRNA against PDCD4 in
A549 cells. The MTT assay indicated a weaker anti-tumour effect of
cisplatin following transfection of PDCD4 siRNA, and the enhanced
growth-inhibitory effect by anti-miR-182 transfection was also
weakened after the addition of PDCD4 siRNA (*P <0.05).
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dictive biomarkers or targets for therapy.
MiRNAs are thought to function as either tumor sup-
pressors or oncogenes though target oncogenes or tumor
suppressor genes during tumorigenesis and development
of cancers [16-18]. miR-182 has been regarded as an
oncogene in most contexts. In a cohort of 253 glioma pa-
tients, high miR-182 expression was found to be a nega-
tive prognostic factor [19]. In melanoma cell lines, Segura
and coworkers showed that high miR-182 expression
stimulated migration and survival. The same group
treated liver metastases in mice with anti -miR-182 and
obtained a lower tumor burden and a lower mir-182-level
than in untreated mice [20]. Also in breast tumors and
cervical cancers miR-182 seems to have an oncogenic im-
pact [21,22]. Previously, Wang M et al. found that miR-
182 was markedly upregulated in human lung cancer cells.
They conducted MTT and colony formation assays to fur-
ther evaluate the effect of miR-182 on lung cancer cell
growth, and they performed transwell and wound healing
assays to evaluate its role in regulating invasion and mi-
gration activity. Their results demonstrate that miR-182
acts as an oncogene in lung cancer [9].
Previous studies demonstrated that the acquired drug
resistance of cancer cells is related to deregulation of
miRNAs such as miR21, miR-503, miR-181a and miR-
620 [23-25]. In the present study, to explore whether the
unregulated oncogene miR-182 was involved in the
NSCLC cells resistant to cisplatin, we transfected miR-
182 inhibitor and its negative control oligonucleotides
into A549 cells. Then MTT assay showed that the miR-
182-suppressed cells were significantly more sensitive to
the therapy of cisplatin than control cells, indicating that
overexpression of miR-182 may involve in chemoresis-
tance of NSCLC cells to cisplatin.
In NSCLC tissues, many onco-miRs/tumor suppressor-
target or tumor suppressor-miRs/onco-target pathways
have been demonstrated to participate in the tumorigen-
esis of lung cancer, including miR7/BCL2 axis, miR-99b/
FGFR3 axis, miR-101/EZH2 axis, miR-192/RB1 axis and
miR-196/HOXA5 axis [26-30]. However, miRNA/target
network was so complex that more and more miRNA/tar-
get axis needs to be elucidated in lung cancer especially
NSCLC. In the present study, We transfected A549 cells
with miR-182 inhibitor or a scrambled miR-182 inhibitor
control. The PDCD4 mRNA and protein were overexpres-
sion in miR-182-suppressed cells compared with controls,
indicating that miR-182 was a negative regulator of
PDCD4. Furthermore, we found that when down regu-
lated of PDCD4 expression by siRNAs, A549 cells be-
came more resistant to the therapy of cisplatin. In
addition, the enhanced growth-inhibitory effect by the
miR-182 inhibitor transfection was weakened after the
addition of PDCD4 siRNA, suggesting that PDCD4 was
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platin. These results established that miR-182 transfer
in combination with cisplatin therapy may be a target to
reverse chemotherapeutic resistance. In addition, fur-
ther research is needed to investigate whether the ex-
pression level of miR-182 in tumor tissue and plasma
might be used as a biomarker to predict platinum based
chemotherapy response in patients with NSCLC.
Conclusion
In conclusion, the results of the present study demon-
strates that overexpression of miR-182 may involve in
chemoresistance of NSCLC cells to cisplatin by down-
regulating PDCD4. This finding suggests that inhibition of
miR-182 may be a useful therapeutic strategy for NSCLC
treatment.
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